NCT00757588.

Trial name or title	Safety and efficacy of saxagliptin plus insulin with or without metformin
Methods	Multicenter double‐blind parallel‐group randomised controlled trial, phase 3 trial
Participants	Type 2 diabetes with inadequate glycaemic control
Interventions	Saxagliptin (5 mg) + insulin vs placebo for saxagliptin + insulin
Outcomes	HbA1c, fasting glucose, insulin dose, blood pressure, (serious) adverse events (hypoglycaemia)
Starting date	22 September 2008
Contact information
Notes	AstraZeneca